Is Semaglutide a GLP-1 Receptor Agonist?

What the GLP-1 receptor actually does, and why semaglutide targets it

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases naturally after eating. It signals to the pancreas to release insulin when blood sugar rises, tells the liver to hold back glucagon, slows the rate at which your stomach empties, and sends satiety messages to the hypothalamus in the brain. The effect is a blunted appetite and steadier blood-sugar response after meals.

Naturally produced GLP-1 breaks down within minutes. Semaglutide is engineered to mimic the hormone but resist that rapid degradation, its half-life is roughly a week, which is what makes once-weekly dosing practical. By binding selectively to the GLP-1 receptor, it sustains those same downstream effects for far longer than the body's own hormone could. You can read more about the pharmacology in the NHS's semaglutide medicines page, which covers how the drug works alongside its safety profile.

The word "agonist" simply means the molecule activates the receptor rather than blocking it. If you want a deeper explanation of that classification, our page on whether semaglutide is a GLP-1 agonist walks through the pharmacology in plain terms. That distinction matters when comparing drug classes: antagonists block; agonists stimulate.

If you want to compare this single-receptor approach with a dual-agonist approach, the page on whether Wegovy is a dual agonist sets out the structural difference clearly.

What the clinical evidence shows for GLP-1 receptor agonism at weight-management doses

The STEP 1 trial (a phase 3 randomised study involving nearly 2,000 adults with obesity but without type 2 diabetes) tested semaglutide 2.4 mg weekly against placebo over 68 weeks. Average body weight fell by around 15% in the active group compared with roughly 2.4% in the placebo group, a difference driven entirely by GLP-1 receptor activation alongside lifestyle changes. The full data were published in the NEJM STEP 1 paper.

That 15% figure is an average across participants who varied considerably in how they responded, some lost more, some less. Weight loss on any GLP-1 medicine is not uniform, and dose titration, individual biology, and behavioural factors all influence outcomes. Clinical trials are the best evidence we have; they cannot predict an individual result.

Semaglutide 2.4 mg is licensed in the UK under the brand name Wegovy. The Wegovy page covers the UK licence conditions, the titration schedule, and the difference between the injection and the oral tablet approved by the MHRA in June 2026. Both formulations work through the same GLP-1 receptor mechanism, though oral bioavailability is lower and the maintenance dose is higher (25 mg daily) to compensate.

One thing worth knowing: semaglutide is a semaglutide agonist at the GLP-1 receptor only, it does not activate the GIP receptor. That makes it pharmacologically distinct from tirzepatide (Mounjaro), which targets both. The practical significance of that difference in weight outcomes is explored on the GLP-1 agonist and Wegovy page.

UK licensing, what Wegovy is actually approved for, and where Ozempic fits

If you have heard the terms Ozempic, Wegovy and Rybelsus used interchangeably online, the confusion is understandable. All three contain semaglutide and all three activate the GLP-1 receptor. The licences, however, are separate and matter legally.

Wegovy (injection) is licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above if at least one weight-related condition is present. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Ozempic is licensed for type 2 diabetes. Rybelsus (oral) is also licensed for type 2 diabetes. Prescribing semaglutide for weight loss specifically requires the Wegovy licence, the MHRA has been clear that Ozempic should not be prescribed for weight loss given the supply pressures and licensing position.

NICE recommended Wegovy for NHS use in England under TA875, within specialist weight-management services and for a maximum of two years. NHS availability remains limited; many people access Wegovy privately through a regulated pharmacy. Treatment typically begins at a lower dose and increases gradually, and our guide to the 500 mcg semaglutide starting dose explains what that first stage of the titration involves. For a broader look at licensed weight-loss options, the weight-loss overview is a sensible starting point.

A prescriber reviews whether semaglutide is appropriate for you individually, past medical history, current medicines, and other factors all feed into that assessment. That clinical review is what makes it a prescription medicine, not an over-the-counter product. If you are considering treatment, the place to start is a proper clinical assessment rather than a classification answer, useful as that is.